Eysz: Gaining Insight into Epilepsy

article image
ARTICLE SUMMARY:

Eysz aims to transform epilepsy care with an AI-based clinical decision support software solution that analyzes passive eye movement data, enabling clinicians to make informed treatment decisions, rather than depend on unreliable patient self-reported information.

The costs of treating epilepsy have risen dramatically each year. Compared to a decade ago, direct costs related to the condition have increased nearly 100% to $28 billion annually. Concerningly, this rise in patient expenses doesn’t correlate with an improvement in outcomes, which have remained at a stagnant rate since the 1990s.

Contributing to this lack of progress is the primary diagnostic tool used in determining seizure medication dosage for epilepsy: patient-self-reported data, which studies have shown to have an accuracy rate of 50% or less. Unreliable data leads to more hospital visits, and for a patient, fear about the stability of their own condition. Not to mention, the pressure of diligent self-tracking and self-reporting can be intrusive to a patient’s lifestyle.

×

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?


Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.

All-Access

Questions?

We're here to help! Please contact us at: